BioInvent: Partnered Programme Enters Late Stage - Redeye
Bildkälla: Stockfoto

BioInvent: Partnered Programme Enters Late Stage - Redeye

Redeye gives its view on mezagitamab, whose phase III start triggered a milestone payment to BioInvent.

Redeye gives its view on mezagitamab, whose phase III start triggered a milestone payment to BioInvent.
Börsvärldens nyhetsbrev
ANNONSER